SELLAS Life Sciences (SLS)

• Market cap: $204M
• 1 day: -2.05%
• 5 days: -11.73%
• 1 month: -30.24%
• 3 months: -7.74%
• 6 months: -5.3%
• Year to date: 33.64%
• 1 year: 12.6%
• 5 years: -45.83%
• 10 years: -100%
• Sector: Healthcare
• Industry: Biotechnology

About: SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.

Employees: 15